Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Quiz|Articles|April 3, 2026
OncLive Weekly News Quiz (4/3/2026): Are You Caught Up on Key Updates in MCL, Cholangiocarcinoma, and More?
Author(s)OncLive Staff
Fact checked by: Chris Ryan
Key Takeaways
- ”, varied openers, complete sentences, ending with periods).
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Which of the following best reflects the findings supporting the FDA’s full approval of brexucabtagene autoleucel (brexu-cel; Tecartus) in relapsed/refractory mantle cell lymphoma?
Advertisement
Related to this article
In case you missed any, read a recap of the episodes of OncLive On Air that aired in July 2026.
The FDA approved RP1 plus nivolumab in advanced melanoma, granted olomorasib breakthrough status in KRAS G12C+ pancreatic cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Updated ASCO Living Guideline recommendations expand frontline therapy for HER2-positive gastroesophageal cancer to include zanidatamab-based regimens.
Faculty convened for a virtual OncLive Scientific Interchange and Workshop to interpret emerging trial data and treatment strategies for systemic mastocytosis.
Paul E. Oberstein, MD, discusses autogene cevumeran, a personalized mRNA vaccine, which is being evaluated for pancreatic ductal adenocarcinoma.
Advertisement
Advertisement
Trending on OncLive
1
ASCO Guideline Update Broadens First-Line Treatment Options for HER2+ Gastroesophageal Cancer
2
CAR T-Cell Therapy Continues to Make Its Case in Early Relapsed Myeloma
3
FDA Awards Fast Track Designation to Safusidenib in IDH1-Mutant Glioma
4
FDA Grants Breakthrough Therapy and Fast Track Status to 68Ga-NYM096 in ccRCC
5